Regulus Therapeutics
RGLS
RGLS was delisted on the 24th of June, 2025.
92 hedge funds and large institutions have $226M invested in Regulus Therapeutics in 2015 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 15 closing their positions.
186% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $3.97M
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
0% more funds holding
Funds holding: 92 → 92 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
40% less capital invested
Capital invested by funds: $377M → $226M (-$151M)
Top Buyers
| 1 |
Axa
Paris,
France
|
+$7.93M |
| 2 |
FCMI
Foresite Capital Management II
Larkspur,
California
|
+$7.33M |
| 3 |
UBS AM
Chicago,
Illinois
|
+$6.43M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$2.26M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$2.13M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$20M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.43M |
| 3 |
Jennison Associates
New York
|
-$4.46M |
| 4 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$3.14M |
| 5 |
Goldman Sachs
New York
|
-$1.17M |
RGLS Hedge Fund Activity: Q3 2015 in Review
92 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Regulus Therapeutics (RGLS) for Q3 2015, worth a combined $226M — down 40% from $377M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new RGLS positions and 15 closed out — a net gain of 1 holder — while 31 added to existing stakes and 23 trimmed.
The largest buyer was Axa, opening a new position worth an estimated $7.93M. The largest seller was State Street, cutting an estimated $20M.
- 92 institutional investors held Regulus Therapeutics (RGLS) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $226M of Regulus Therapeutics stock for Q3 2015, down 40% quarter-over-quarter.
- 16 funds opened new Regulus Therapeutics positions in Q3 2015 and 15 closed out, a net change of +1 holder.
- The largest Regulus Therapeutics buyer in Q3 2015 was Axa, an estimated $7.93M added.
- The largest Regulus Therapeutics seller in Q3 2015 was State Street, an estimated $20M sold.
Based on aggregated 13F filings for Q3 2015.